Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2022-11-10 00:00:00 ET · period of report 2022-11-09 · accession 0000899243-22-035519 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-11-10 | 2022-11-09 | LGND | Espinoza Octavio | CFO | S - Sale | $75.64 | -1,696 | 8,857 | -16% | -$128.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-11-09 | S | D | 1,696 | $75.64 | 8,857 | D | — | — |